Analysts Set Schrödinger, Inc. (NASDAQ:SDGR) Target Price at $32.90

Shares of Schrödinger, Inc. (NASDAQ:SDGR) have earned a consensus rating of “Moderate Buy” from the eleven research firms that are presently covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $32.90.

SDGR has been the subject of several research reports. Morgan Stanley decreased their target price on Schrödinger from $43.00 to $30.00 and set an “equal weight” rating for the company in a research note on Wednesday, August 21st. BMO Capital Markets raised their price objective on shares of Schrödinger from $25.00 to $28.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th.

Insiders Place Their Bets

In other news, insider Margaret Dugan sold 1,531 shares of the firm’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $17.78, for a total value of $27,221.18. Following the completion of the sale, the insider now owns 13,469 shares of the company’s stock, valued at $239,478.82. This trade represents a 10.21 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 8.60% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of SDGR. Stephens Investment Management Group LLC grew its stake in Schrödinger by 39.6% during the 3rd quarter. Stephens Investment Management Group LLC now owns 1,539,870 shares of the company’s stock valued at $28,565,000 after acquiring an additional 436,789 shares in the last quarter. Millennium Management LLC grew its position in Schrödinger by 2,868.8% during the second quarter. Millennium Management LLC now owns 487,831 shares of the company’s stock valued at $9,435,000 after purchasing an additional 471,399 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Schrödinger by 7.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 500,461 shares of the company’s stock valued at $9,679,000 after buying an additional 35,036 shares during the period. Sumitomo Mitsui Trust Group Inc. lifted its position in Schrödinger by 1.4% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,191,054 shares of the company’s stock worth $40,644,000 after buying an additional 29,920 shares in the last quarter. Finally, Quest Partners LLC boosted its stake in shares of Schrödinger by 861.0% during the 3rd quarter. Quest Partners LLC now owns 43,773 shares of the company’s stock valued at $812,000 after buying an additional 39,218 shares during the period. 79.05% of the stock is owned by institutional investors and hedge funds.

Schrödinger Trading Up 2.6 %

Schrödinger stock opened at $22.01 on Friday. Schrödinger has a 52 week low of $16.67 and a 52 week high of $38.00. The stock has a market cap of $1.60 billion, a price-to-earnings ratio of -9.41 and a beta of 1.50. The company’s 50-day moving average price is $18.76 and its two-hundred day moving average price is $20.18.

Schrödinger (NASDAQ:SDGR) last announced its earnings results on Tuesday, November 12th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.12). The firm had revenue of $35.30 million for the quarter, compared to the consensus estimate of $41.25 million. Schrödinger had a negative return on equity of 35.77% and a negative net margin of 91.84%. Schrödinger’s revenue for the quarter was down 17.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.86) EPS. Research analysts expect that Schrödinger will post -2.29 earnings per share for the current fiscal year.

About Schrödinger

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.